Published on Roswell Park Cancer Institute (http://www.roswellpark.org)

Title A Phase I Study of the P13-Kinase Inhibitor BKM120 in Combination with Docetaxel in Patients with Advanced Solid Tumors
Contact FS
Principal Investigator Alex Adjei, MD PhD
Study Number 186510
Phase1
Summary The purpose of the study is to find the highest dose of an investigational drug BKM120 that can be given to patients with cancer in combination with commonly used chemotherapy drug Docetaxel without causing severe side effects.
Eligibility
  • Please see Clinical Trials.gov listing for Eligibility Criteria.  
For more information about the clinical study go to Clinicaltrial.Gov
Source URL (retrieved on 05/23/2013 - 8:30am): http://www.roswellpark.org/clinical-trials/list/186510-0